Shroom-Therapy Startup Edges Toward FDA Approval

1/8/2020

This Bloomberg article discusses a psychedelic mushroom therapy startup called Compass Pathways and its progress towards gaining approval from the U.S. Food and Drug Administration (FDA). The company is conducting clinical trials with psilocybin, the active compound in psychedelic mushrooms, as a potential treatment for depression. The article highlights the positive results of previous studies and the growing interest in psychedelic-assisted therapy for mental health disorders. It also touches on the challenges faced by Compass Pathways and the potential impact of FDA approval on the psychedelic therapy industry. The article provides insights into the potential future of psychedelic medicine and its impact on mental health treatments.

psychedelic therapy ꞏ mental health ꞏ fda approval ꞏ psychedelic research ꞏ alternative medicine ꞏ psychedelic mushrooms ꞏ psilocybin therapy ꞏ mental wellness ꞏ psychedelic drugs ꞏ psychedelic experiences ꞏ therapeutic uses ꞏ mental illness ꞏ treatment options ꞏ clinical trials ꞏ neurobiology ꞏ psychedelic medicine ꞏ psychedelic-assisted therapy ꞏ consciousness exploration ꞏ psychedelic substances ꞏ mind-altering effects ꞏ therapeutic potential ꞏ psychedelic renaissance ꞏ psychedelic healing ꞏ mental well-being ꞏ psychedelic integration ꞏ mental health disorders ꞏ psychedelic science ꞏ drug regulation ꞏ psychedelic studies ꞏ therapeutic breakthroughs ꞏ psychedelic reformation ꞏ psychopharmacology ꞏ psychotherapy ꞏ holistic medicine ꞏ psychoactive compounds ꞏ therapeutic innovation ꞏ fda regulations ꞏ psychedelic treatments ꞏ medical breakthroughs ꞏ transformative experiences ꞏ end-of-life therapy ꞏ psychedelics in psychiatry ꞏ therapeutic modalities ꞏ mental health treatment